10 results about "Hematopoietic progenitor" patented technology

A method is provided for recruiting hematopoietic progenitor cells from the bone marrow of a target to the peripheral blood. The method comprises (a) administering an effective dose of natalizumab to the target, and (b) administering an effective dose of a CXCR4 inhibitor to the target, at least 48 hours after step (a). The use of such recruitment procedures in cell collection and therapy is also provided.

The present invention relates to processes for the in vitro production of hematopoietic cells, comprising contacting hematopoietic progenitors with a DNTM3A inhibitor, hematopoietic cells comprising said DNTM3A inhibitor and uses thereof.

Disclosed herein are compounds that are Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors having a structure according to Formula I, and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.

The present disclosure provides methods for making bone marrow hematopoietic progenitors lacking NF-κB p50 protein subunit (p50) and STAT6, or bone marrow hematopoietic progenitors lacking NF-κB p50 protein subunit and NF-κB p52 protein subunit. The progenitor cells are expanded, exposed to a myeloid cytokine, and provided intravenously to treat various malignancies. The infused cells have the potential to generate mature granulocytes, monocytes, macrophages, and dendritic cells. Methods for the genetically manipulation of a subject's hematopoietic progenitors during the expansion phase to reduce or eliminate expression of p50, p52, and / or STAT6 are also contemplated, and these progenitor cells may be combined with other therapeutic agents to maximize efficacy.

The invention provides methods for generating human CD34+, CD43+, and CD90+ hematopoietic progenitor cells from hematopoietic stem cells. The methods include the use of chemically-defined culture media. Isolated cell populations are also provided.

The invention provides methods for generating human CD34+, CD43+, and CD90+ hematopoietic progenitor cells from hematopoietic stem cells. The methods include the use of chemically-defined culture media. Isolated cell populations are also provided.

The method of generating multipotent stem cells is a method for producing and / or expanding multipotent stem cells by delivering at least one reprogramming protein into somatic cells. The at least one reprogramming protein includes a Master Regulator (MR) protein, which may be BAZ2B, ZBTB20, ZMAT1, CNOT8, KLF12, DMTF1, HBP1, or FLI1. The bromodomain protein BAZ2B, in particular, was identified by first generating bi-species heterokaryons by fusing Tcf7l1− / − murine embryonic stem cells (ESCs) with human B-cell lymphocytes. Reprogramming of the B-cell nuclei to a multipotent state was tracked by human mRNA transcript profiling at multiple timepoints. Interrogation of a human B-cell regulatory network with gene expression signatures collected from such reprogramming time series identified eight candidate Master Regulator proteins, which were validated in human cord blood-derived hematopoietic progenitor and lineage-committed cells.

The present invention relates to methods for deriving human hematopoietic progenitors, primitive macrophages, and microglial cells from human pluripotent stem cells. In particular, provided herein are highly efficient and reproducible methods of obtaining human primitive macrophages and microglia from human pluripotent stem cells, where the primitive macrophages and microglia can be suitable for clinically relevant therapeutic applications.

The application discloses an isofuranone compound, a medicine combination and use thereof, and the isofuranone compound disclosed by the application can efficiently and selectively degrade hematopoietic progenitor kinase 1 protein, and has no degradation activity on other proteins in the same family. Compared with a small molecule inhibitor of hematopoietic progenitor kinase 1, the isofuranone compound can more efficiently stimulate T cell anti-tumor immune response, release effector cytokines, and has stronger anti-tumor activity.

The present invention provides a method for producing natural killer (NK) cells or precursor cells thereof from pluripotent stem cells, comprising a) a step of in vitro inducing hematopoietic progenitor cells (HPC) from pluripotent stem cells, b) a step of in vitro expanding HPC, and c) a step of in vitro inducing NK cells or precursor cells thereof from HPC and inhibiting histone methyltransferase and / or aromatic hydrocarbon receptors (AHR) in one or more of steps a) to c); and a method comprising (1) a step for forming pluripotent stem cell spheres having an average particle diameter of 200 [mu] m or more in a first culture medium, (2) a step for inducing the pluripotent stem cell spheres obtained in step (1) into a cell population containing HPC by three-dimensional culture using a second culture medium containing a histone methyltransferase inhibitor and / or an AHR antagonist, and (3) a step for inducing the pluripotent stem cell spheres obtained in step (2) into a cell population containing HPC. And (3) a step in which the cell population containing HPC obtained in step (2) is induced into a cell population containing NK cells or precursor cells thereof by three-dimensional culture using a third culture medium containing a histone methyltransferase inhibitor and / or an AHR antagonist, and one or more of steps (1) to (3) are performed by a perfusion culture method. Steps (1) to (3) are preferably performed by a continuous perfusion culture method.